SCHEMBL14595149

SCHEMBL14595149

Cc1cccc(-c2nnc(-c3ccc4ccccc4c3)o2)c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 9/20 0.77
HPGD P15428 6/20 0.77
TSHR P16473 4/20 0.77
ALDH1A1 P00352 3/20 0.77
HSD17B10 Q99714 3/20 0.77
CYP1A2 P05177 3/20 0.77
CYP2C9 P11712 2/20 0.77
CYP3A4 P08684 1/20 0.77
NPC1 O15118 8/20 0.73
RAB9A P51151 8/20 0.73
TP53 P04637 5/20 0.65
POLB P06746 3/20 0.65
CA1 P00915 2/20 0.57
CA2 P00918 2/20 0.57
NFKB1 P19838 2/20 0.54
NFKB2 Q00653 2/20 0.54
RELA Q04206 2/20 0.54
KDM4E B2RXH2 3/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9195816 0.86 SMN1; SMN2 (0.79) SMN1; SMN2HPGDTSHRALDH1A1HSD17B10
SCHEMBL11674120 0.86 SMN1; SMN2 (0.89) SMN1; SMN2HPGDTSHRALDH1A1HSD17B10
SCHEMBL11840510 0.85 NPC1 (0.93) SMN1; SMN2HPGDTSHRALDH1A1HSD17B10
SCHEMBL27477472 0.84 SMN1; SMN2 (0.77) SMN1; SMN2HPGDTSHRALDH1A1HSD17B10
SCHEMBL13882293 0.84 SMN1; SMN2 (0.85) SMN1; SMN2HPGDTSHRALDH1A1HSD17B10
SCHEMBL12634931 0.83 NPC1 (0.83) SMN1; SMN2HPGDTSHRALDH1A1HSD17B10
SCHEMBL16675211 0.83 SMN1; SMN2 (0.82) SMN1; SMN2HPGDTSHRALDH1A1HSD17B10
SCHEMBL6311375 0.82 CYP2A6 (0.60) SMN1; SMN2HPGDTSHRALDH1A1HSD17B10
SCHEMBL6984735 0.81 SMN1; SMN2 (0.73) SMN1; SMN2HPGDTSHRALDH1A1HSD17B10
SCHEMBL19131306 0.81 NPC1 (0.86) SMN1; SMN2HPGDTSHRALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070060582-A1 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases FINK CYNTHIA A 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060582-A1 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases BRAF, RAF1, NRAS SMN1; SMN2 4098/4885HPGD 1498/4885TSHR 2713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.